CD247 and cancer: Dr. Michel Sadelain’s laboratory at Memorial Sloan Kettering Cancer Center (MSKCC) designed a chimeric receptor that combines the CD3ζ and CD28 endodomains, which provides both activation and co-stimulatory signals, and leads to enhanced antigen-dependent proliferation, interleukin-2 production, and cancer cell killing in vitro (45, 46).